Skip to main content
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
2.920
+0.160 (5.80%)
At close: May 1, 2024, 4:00 PM
2.930
+0.010 (0.34%)
After-hours: May 1, 2024, 7:02 PM EDT

Allogene Therapeutics Revenue

In the year 2023, Allogene Therapeutics had annual revenue of $95.00K, a decrease of -39.10%. Revenue in the quarter ending December 31, 2023 was $-44.00K with 10.00% year-over-year growth.

Revenue (ttm)
$95.00K
Revenue Growth
-39.10%
P/S Ratio
5,247.49
Revenue / Employee
$409
Employees
232
Market Cap
498.51M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202395.00K-61.00K-39.10%
Dec 31, 2022156.00K-113.93M-99.86%
Dec 31, 2021114.09M--
Dec 31, 20200--
Dec 31, 20190--
Dec 31, 20180--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
PetIQ 1.10B
Orthofix Medical 746.64M
LifeMD 152.55M
Avid Bioservices 136.74M
UroGen Pharma 82.71M
Oculis Holding AG 1.05M
Revenue Rankings

ALLO News

More News